Dublin, Jan. 29, 2026 (GLOBE NEWSWIRE) — The “Reflux Testing Products Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031” has been added to ResearchAndMarkets.com’s offering.
The Global Reflux Testing Products Market is projected to expand from USD 3.72 Billion in 2025 to USD 5.01 Billion by 2031, registering a compound annual growth rate of 5.09%.
This sector includes various diagnostic tools such as esophageal manometry systems, catheter-based impedance-pH monitors, and wireless pH capsules, all utilized to measure and identify the regurgitation of stomach contents into the esophagus.
A major force driving this expansion is the increasing global prevalence of gastroesophageal reflux disease (GERD), which requires precise objective verification to diagnose conditions and plan surgeries effectively. Additionally, the growing number of aging individuals and rising obesity rates further fuel the market by enlarging the population susceptible to chronic acid reflux, necessitating thorough diagnostic assessments.
However, the industry encounters a notable obstacle due to the discomfort and non-compliance linked to conventional catheter-based monitoring, which discourages patients from proceeding with essential tests. This issue underscores the conflict between the need for diagnosis and what patients are willing to endure. As reported by the International Society for Diseases of the Esophagus in 2025, the global burden of GERD has escalated to roughly 826 million cases, a figure that emphasizes the urgent and expanding need for efficient reflux testing solutions.
Market Drivers
The rising incidence of Barrett’s esophagus and esophageal adenocarcinoma act as a vital clinical imperative driving the need for accurate reflux testing. Because chronic gastroesophageal reflux harms the esophageal lining, screening for pre-cancerous cellular changes through rigorous impedance and pH monitoring is essential.
This urgency transforms testing from simple symptom management into a critical requirement for preventative oncology. As stated by the American Cancer Society in their January 2024 ‘Cancer Facts & Figures 2024’, an estimated 22,370 new esophageal cancer cases were projected for the United States, reinforcing the necessity for early identification via advanced diagnostic instruments.
Simultaneously, rapid progress in wireless pH monitoring is transforming the sector by addressing the compliance issues common with catheter-based systems. These modern capsule devices enable extended data recording without causing physical distress, thereby encouraging clinicians to rely on objective evidence of reflux.
This technological evolution is mirrored in the financial results of leading companies; for instance, Medtronic’s ‘Fourth Quarter Fiscal 2024 Financial Results’ from May 2024 showed their Medical Surgical Portfolio generated $2.2 billion in worldwide revenue, underscoring the segment’s commercial magnitude. Furthermore, the market is supported by growing obesity rates that worsen reflux symptoms, with the World Health Organization reporting in 2024 that over 1 billion individuals globally are living with obesity, creating a massive demographic in need of long-term diagnostic solutions.
Market Challenges
The discomfort and lack of compliance associated with standard catheter-based monitoring represent a significant hurdle that directly restricts revenue growth in the Global Reflux Testing Products Market. Procedures like impedance-pH monitoring and esophageal manometry generally involve the transnasal insertion of a catheter, which often triggers gagging, anxiety, and substantial physical irritation.
This invasive aspect causes considerable friction during care, leading many eligible patients to decline confirmatory tests or end procedures prematurely. As a result, medical providers frequently resort to empirical medication rather than insisting on objective diagnostics, thereby diminishing the usage of testing devices and curbing market penetration.
This reluctance forms a specific bottleneck that hampers the market’s ability to fully benefit from the increasing prevalence of digestive conditions. According to the American Gastroenterological Association, over 30% of adults in the United States reported experiencing symptoms of gastroesophageal reflux disease on at least a weekly basis in 2024. This statistic indicates a vast addressable patient group that remains underserved by diagnostic products largely because of the tolerability challenges embedded in conventional catheter-based protocols.
Market Trends
The integration of Artificial Intelligence into reflux data analysis is transforming diagnostic software by evolving from basic metrics to automated pattern recognition. Traditional tracings produce extensive datasets where minor variations, such as non-acid reflux episodes, might be missed during manual examination.
AI algorithms now support clinicians by pinpointing these anomalies with great accuracy, reducing variability between observers and boosting diagnostic certainty in difficult cases. This technological advancement is backed by strong clinical evidence; a study in JMIR Medical Informatics titled ‘Diagnostic Accuracy of Artificial Intelligence in Endoscopy: Umbrella Review’ from July 2024 noted that AI models achieved a sensitivity of 97% in diagnosing gastroesophageal reflux disease, significantly surpassing standard manual methods.
The shift toward prolonged multi-day ambulatory monitoring marks a clinical progression designed to resolve the shortcomings of standard 24-hour protocols, which frequently miss daily symptom fluctuations. Physicians are increasingly favoring extended wireless monitoring periods lasting up to 96 hours to conclusively identify pathologic acid exposure in unclear cases, rather than depending on shorter observation windows.
This change is motivated by evidence showing that longer testing durations considerably improve the identification of eligible patients who might otherwise be overlooked. According to the American College of Gastroenterology’s September 2024 study ‘Diagnostic Yield of Prolonged Wireless pH vs 24-hour pH-Impedance Monitoring’, the diagnostic yield for confirming gastroesophageal reflux disease reached 50% with prolonged wireless monitoring, compared to just 27% using traditional 24-hour impedance monitoring.
Key Players Profiled in the Reflux Testing Products Market
- Medtronic PLC
- Sierra Instruments, Inc.
- Respiratory Technology Corporation
- Ethicon, Inc.
- Medical Measurement Systems BV
- AstraZeneca PLC
- Diversatek, Inc.
- FLSmidth A/S
- Laborie Medical Technologies Corp.
- DRG Instruments GmbH
Report Scope
In this report, the Global Reflux Testing Products Market has been segmented into the following categories:
Reflux Testing Products Market, by Product Type:
- Catheter Based Testing Products
- Capsule Based Testing Products
- Reflux Testing Probes
- Others
Reflux Testing Products Market, by Disease Indication:
- Barrett’s Esophagus
- Reflux Esophagitis
- Esophageal Adenocarcinoma
Reflux Testing Products Market, by End User:
- Hospitals &Clinics
- Ambulatory Surgical Centers
- Others
Reflux Testing Products Market, by Region:
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 182 |
| Forecast Period | 2025 – 2031 |
| Estimated Market Value (USD) in 2025 | $3.72 Billion |
| Forecasted Market Value (USD) by 2031 | $5.01 Billion |
| Compound Annual Growth Rate | 5.0% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/xscda1
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Reflux Testing Products Market
